Edition:
United States

Bio-Techne Corp (TECH.OQ)

TECH.OQ on NASDAQ Stock Exchange Global Select Market

129.51USD
15 Dec 2017
Change (% chg)

$1.75 (+1.37%)
Prev Close
$127.76
Open
$128.16
Day's High
$129.78
Day's Low
$127.78
Volume
210,539
Avg. Vol
63,719
52-wk High
$135.69
52-wk Low
$95.68

Chart for

About

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $4,851.73
Shares Outstanding(Mil.): 37.46
Dividend: 0.32
Yield (%): 0.99

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Women In Bio announces that Alpna Seth joins Bio-Techne's board

* Women In Bio announces that Alpna Seth joins Bio-Techne's board of directors Source text for Eikon:

Nov 07 2017

BRIEF-Bio-Techne releases Q1 adjusted earnings per share $0.90

* Q1 earnings per share view $0.88 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Oct 31 2017

BRIEF-Bio-Techne adds two new directors to its board

* Bio-Techne adds two new directors to its board Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-Bio-Techne releases serological assay to detect Zika virus infections

* Bio-Techne releases a highly sensitive and specific serological assay to detect Zika virus infections

Sep 06 2017

BRIEF-Bio-Techne acquires Trevigen Inc

* Bio-Techne Corp says transaction is financed through available cash on hand

Sep 05 2017

Earnings vs. Estimates